Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

McKesson Corp Stock Research

MCK

444.38USD+1.35(+0.30%)Market Closed
Watchlist

Market Summary

USD444.38+1.35
Market Closed
0.30%

MCK Alerts

  • 1 major insider sales recently.

MCK Stock Price

MCK RSI Chart

MCK Valuation

Market Cap

60.2B

Price/Earnings (Trailing)

16.06

Price/Sales (Trailing)

0.21

EV/EBITDA

12.11

Price/Free Cashflow

12.95

MCK Price/Sales (Trailing)

MCK Profitability

EBT Margin

1.67%

Return on Equity

-150.36%

Return on Assets

5.71%

Free Cashflow Yield

7.72%

MCK Fundamentals

MCK Revenue

Revenue (TTM)

284.0B

Revenue Y/Y

10.91%

Revenue Q/Q

8.09%

MCK Earnings

Earnings (TTM)

3.8B

Earnings Y/Y

24.74%

Earnings Q/Q

21.73%

Price Action

52 Week Range

331.75446.95
(Low)(High)

Last 7 days

2.5%

Last 30 days

4.7%

Last 90 days

6.7%

Trailing 12 Months

29.2%

MCK Financial Health

Current Ratio

0.92

Debt/Equity

-2.61

Debt/Cashflow

1.12

MCK Investor Care

Dividend Yield

0.49%

Dividend/Share (TTM)

2.16

Buy Backs (1Y)

6.03%

Diluted EPS (TTM)

26.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for MCK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-08
TYLER BRIAN S.
sold
-10,668,500
422
-25,246
chief executive officer
2023-09-06
TYLER BRIAN S.
sold
-1,602,770
407
-3,938
chief executive officer
2023-08-11
TYLER BRIAN S.
sold
-1,527,240
440
-3,471
chief executive officer
2023-08-11
TYLER BRIAN S.
acquired
551,889
159
3,471
chief executive officer
2023-08-03
TYLER BRIAN S.
sold
-1,664,200
422
-3,938
chief executive officer
2023-07-21
KNAUSS DONALD R
acquired
-
-
773
-
2023-07-21
Mantia Linda Provie
acquired
-
-
483
-
2023-07-21
Martinez Maria
acquired
-
-
483
-
2023-07-06
TYLER BRIAN S.
sold
-1,650,060
419
-3,938
chief executive officer
2023-06-29
TYLER BRIAN S.
sold
-1,457,820
420
-3,471
chief executive officer

1–10 of 50

Which funds bought or sold MCK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-69.18
-9,786,000
5,745,610
0.02%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
3,543
21,144
-%
2023-09-20
BARCLAYS PLC
added
110
129,655,000
214,768,000
0.14%
2023-09-12
Farther Finance Advisors, LLC
added
1.26
30,498
172,206
0.04%
2023-09-07
ST GERMAIN D J CO INC
new
-
4,273
4,273
-%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
reduced
-1.2
1,062,790
6,784,800
0.78%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
285
1,710
-%
2023-09-05
Westshore Wealth, LLC
reduced
-5.36
30,676
256,539
0.13%
2023-08-30
Western Wealth Management, LLC
reduced
-0.44
250,029
1,532,740
0.13%
2023-08-25
EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC
added
0.42
2,468,000
14,500,000
2.00%

1–10 of 49

Latest Funds Activity

Are funds buying MCK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MCK
No. of Funds

Schedule 13G FIlings of McKesson

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.08%
12,869,151
SC 13G/A
Feb 03, 2023
blackrock inc.
8.3%
11,784,945
SC 13G/A
Feb 10, 2022
vanguard group inc
10.15%
15,497,451
SC 13G/A
Feb 01, 2022
blackrock inc.
8.6%
13,171,252
SC 13G/A
Feb 16, 2021
capital ventures international
0.5%
865,164
SC 13G/A
Feb 10, 2021
vanguard group inc
10.12%
16,251,909
SC 13G/A
Jan 29, 2021
blackrock inc.
8.7%
13,969,975
SC 13G/A
Oct 13, 2020
vanguard group inc
10.17%
16,496,553
SC 13G/A
Mar 18, 2020
capital ventures international
6.6%
10,631,600
SC 13G
Feb 12, 2020
vanguard group inc
8.72%
15,715,599
SC 13G/A

Recent SEC filings of McKesson

View All Filings
Date Filed Form Type Document
Sep 11, 2023
4
Insider Trading
Sep 08, 2023
144
Notice of Insider Sale Intent
Sep 07, 2023
4
Insider Trading
Sep 06, 2023
144
Notice of Insider Sale Intent
Aug 14, 2023
4
Insider Trading
Aug 11, 2023
144
Notice of Insider Sale Intent
Aug 07, 2023
4
Insider Trading
Aug 03, 2023
144
Notice of Insider Sale Intent
Aug 03, 2023
S-8
Employee Benefits Plan
Aug 02, 2023
10-Q
Quarterly Report

MCK Fair Value

Loading...

Peers (Alternatives to McKesson)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
467.0B
348.5B
3.34% 0.09%
22.12
1.34
13.69% 15.63%
60.2B
284.0B
4.66% 29.21%
16.06
0.21
5.81% 168.62%
36.3B
254.4B
-3.53% 22.40%
21.47
0.14
7.66% -8.27%
22.5B
205.0B
1.19% 35.81%
86.35
0.11
13.04% 127.97%
9.6B
12.6B
-3.03% 11.42%
20.89
0.76
-0.94% -29.54%
MID-CAP
6.3B
937.9M
8.58% 4.73%
493.98
6.75
17.97% 120.64%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
3.1B
4.4B
-6.45% -20.59%
9.74
0.71
-16.06% -30.43%
2.9B
6.5B
-11.56% 19.94%
13.35
0.44
1.83% 10.70%
SMALL-CAP
1.9B
1.5B
-13.30% 52.58%
-145.95
1.23
12.20% -155.34%
1.4B
999.1M
-5.56% -8.21%
25.42
1.37
10.42% 21.37%
1.2B
10.1B
-3.45% -37.72%
-12.19
0.12
2.62% -163.74%
768.0M
3.0B
-2.86% -9.13%
-7.45
0.26
11.66% -12.20%
557.4M
998.8M
-4.59% 132.73%
-15.14
0.56
6.84% -158.04%

McKesson News

MarketWatch
McKesson Corp. stock rises Wednesday, outperforms market.
MarketWatch,
2 hours ago
InvestorsObserver
Investor's Business Daily

Returns for MCK

Cumulative Returns on MCK

13.9%


10-Year Cumulative Returns

15.9%


7-Year Cumulative Returns

28.4%


5-Year Cumulative Returns

44.6%


3-Year Cumulative Returns

Risks for MCK

What is the probability of a big loss on MCK?

33.1%


Probability that McKesson stock will be more than 20% underwater in next one year

10%


Probability that McKesson stock will be more than 30% underwater in next one year.

0%


Probability that McKesson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MCK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if McKesson was unfortunately bought at previous high price.

Drawdowns

Financials for McKesson

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.6%284,040276,711273,903272,027268,446263,966257,006250,991245,223238,228237,621234,194231,002231,051224,945221,981217,440214,319213,518210,927209,913
Cost Of Revenue------------------202,565---
Gross Profit0.0%12,35712,35812,61012,86413,12113,13013,10912,83212,48012,14812,18712,06911,93612,02311,88811,82511,76211,75411,62811,37311,403
Operating Expenses-0.8%7,9127,9778,5769,77310,61511,09210,69418,07717,63017,18817,3689,5289,4039,53410,83710,45110,32510,86811,11710,71111,191
  S&GA Expenses-1.1%7,6877,7768,3439,54510,26410,53710,2309,4168,9848,8498,8338,6688,3889,182---8,437---
  R&D Expenses--------------96.00---71.00---
EBITDA-100.0%-5,1264,8063,6132,8062,8663,362-4,248-4,019-3,930-3,7303,9172,3412,3155008672,4301,8231,4001,4421,029
EBITDA Margin-100.0%-0.02*0.02*0.01*0.01*0.01*0.01*-0.02*-0.02*-0.02*-0.02*0.02*0.01*0.01*0.00*0.00*0.01*0.01*0.01*0.01*0.00*
Interest Expenses0.8%250248212184174178187201206217210200-249---264---
Earnings Before Taxes1.8%4,7154,6304,3453,1742,3721,9282,310-5,330-5,117-5,034-4,8622,7951,1701,144-690-3341,223610149196-213
EBT Margin-100.0%-0.02*0.02*0.01*0.01*0.01*0.01*-0.02*-0.02*-0.02*-0.02*0.01*0.01*0.00*0.00*0.00*0.01*0.00*0.00*0.00*0.00*
Net Income5.3%3,7503,5603,1412,0551,3961,1141,412-4,807-4,497-4,539-4,1842,228921900-917-63459534.00-316118-380
Net Income Margin-100.0%-0.01*0.01*0.01*0.01*0.00*0.01*-0.02*-0.02*-0.02*-0.02*0.01*0.00*0.00*0.00*0.00*0.00*0.00*0.00*0.00*0.00*
Free Cashflow-100.0%-4,7694,3214,0714,7494,0464,5064,2903,5104,0915,4134,0823,0164,0123,2563,1854,6343,6102,7202,9052,112
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.8%64,09662,32062,69063,08162,29563,29863,70863,60162,89465,01561,84561,55857,66661,24760,87358,99461,68059,67261,01161,42161,282
  Current Assets2.8%45,53944,29244,65746,44845,38346,23146,49845,58043,35045,38242,36842,34538,68242,22239,39037,35338,42838,46538,31938,54438,214
    Cash Equivalents-43.7%2,6364,6782,7742,9162,2333,9352,7542,1512,4236,2783,5773,0912,6134,0232,0651,3561,9472,9811,8492,1182,199
  Inventory4.2%20,51019,69120,65719,87619,50518,70219,02419,34220,01619,20019,21118,43516,60716,73417,02016,35616,60416,70916,95116,67116,364
  Net PPE-0.2%2,1722,1772,1402,0712,0832,0922,0642,2222,5492,5812,5182,4712,3922,3652,4082,4932,4662,5482,5032,4882,483
  Goodwill0.2%9,9719,9479,9349,2399,3689,4519,4629,4739,5209,4939,5119,4149,4199,3609,4569,4083889,35838624610,585
  Current Liabilities1.0%48,42247,95748,00648,35747,20148,46647,45246,07543,83544,10341,93042,72438,60042,62440,05537,14537,95237,62637,42438,86338,348
  Short Term Borrowings---617---372---152---2,109549--1,0481,3942,033
  Long Term Debt21.3%5,6114,6265,4524,8134,9765,080--6,4246,4066,467--6,335---7,265---
    LT Debt, Current------------1,7601,0531,0521,0073023103301,1201,1261,127
    LT Debt, Non Current-------5,5185,946-6,406-5,8486,3956,3356,7347,3427,3827,2657,6166,5686,592
Shareholder's Equity----------175-6,0905,6535,3096,3856,6928,0688,2879,3899,5349,647
  Retained Earnings7.2%13,18212,29511,58210,5799,7329,0308,7348,8128,6188,2027,59513,89013,38413,02212,07511,96512,77012,40913,27613,35412,932
  Additional Paid-In Capital1.0%7,8247,7477,5367,6097,3507,2757,4117,3117,0576,9256,8476,7806,7116,6636,6146,5736,4836,4356,3216,4116,372
Shares Outstanding-136-140143144-152154156-160162162-179183188-194198202
Minority Interest-1.4%362367366518532480487484484196200200207217211210194193204208240
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-2.2%5,0485,1594,7214,4305,1154,4344,9174,7533,9824,5425,8264,4923,3634,3743,6153,5595,0464,0363,1653,3242,543
Cashflow From Investing-34.7%-730-542-11518449.00-89.00-477-294-384-415-380-572-580-579-639-683-635-1,381-2,192-2,111-2,270
Cashflow From Financing7.7%-4,030-4,368-5,167-4,180-5,351-6,321-4,849-5,186-3,905-1,693-3,656-1,932-1,801-2,734-2,798-3,628-4,640-2,227-1,620-1,614-412
  Dividend Payments1.0%295292287282279277273270271276281286293294298301296292286280271
  Buy Backs-8.4%3,3343,6385,0303,7823,5383,5162,2581,7611,7507424837521,2331,9342,2022,2022,0321,6392,1451,8951,716

MCK Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]  
Revenues$ 74,483$ 67,154
Cost of sales(71,461)(64,131)
Gross profit3,0223,023
Selling, distribution, general, and administrative expenses(1,870)(1,959)
Claims and litigation charges, net0(5)
Restructuring, impairment, and related charges, net(52)(23)
Total operating expenses(1,922)(1,987)
Operating income1,1001,036
Other income, net3815
Interest expense(47)(45)
Income from continuing operations before income taxes1,0911,006
Income tax expense(94)(199)
Income from continuing operations997807
Income from discontinued operations, net of tax02
Net income997809
Net income attributable to noncontrolling interests(39)(41)
Net income attributable to McKesson Corporation$ 958$ 768
Diluted  
Continuing operations (in usd per share)$ 7.02$ 5.25
Discontinued operations (in usd per share)00.01
Total (in dollars per share)7.025.26
Basic  
Continuing operations (in usd per share)7.075.31
Discontinued operations (in usd per share)00.01
Total (in dollars per share)$ 7.07$ 5.32
Weighted-average common shares outstanding  
Diluted (in usd per share)136.6145.9
Basic (in shares)135.5144.2

MCK Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Current assets  
Cash and cash equivalents$ 2,636$ 4,678
Receivables, net21,86019,410
Inventories, net20,51019,691
Prepaid expenses and other533513
Total current assets45,53944,292
Property, plant, and equipment, net2,1722,177
Operating lease right-of-use assets1,6931,635
Goodwill9,9719,947
Intangible assets, net2,2212,277
Other non-current assets2,5001,992
Total assets64,09662,320
Current liabilities  
Drafts and accounts payable43,98242,490
Current portion of long-term debt50968
Current portion of operating lease liabilities300299
Other accrued liabilities4,0904,200
Total current liabilities48,42247,957
Long-term debt5,6114,626
Long-term deferred tax liabilities1,1391,387
Long-term operating lease liabilities1,4621,402
Long-term litigation liabilities6,6286,625
Other non-current liabilities2,0741,813
McKesson Corporation stockholders’ deficit  
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively33
Additional paid-in capital7,8247,747
Retained earnings13,18212,295
Accumulated other comprehensive loss(848)(905)
Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively(21,763)(20,997)
Total McKesson Corporation stockholders’ deficit(1,602)(1,857)
Noncontrolling interests362367
Total deficit(1,240)(1,490)
Total liabilities and deficit$ 64,096$ 62,320
Brian S. Tyler
65535
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.